国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2010年
10期
585-587
,共3页
非小细胞肺癌%吉非替尼%维持治疗%有效性%安全性
非小細胞肺癌%吉非替尼%維持治療%有效性%安全性
비소세포폐암%길비체니%유지치료%유효성%안전성
Non-small cell lung cancer%Gefitinib%Maintenance therapy%Effectivity%safety
目的 观察吉非替尼对既往化学治疗有效的晚期(Ⅳ期)非小细胞肺癌维持治疗的疗效和安全性.方法 在15例经病理学确诊的非小细胞肺癌经4～6个周期含铂类方案化疗后取得临床完全缓解和部分缓解患者中,随机选取2例Ⅳ期肺腺癌患者予以吉非替尼维持治疗,250 mg/次,1次/d,口服.结果 2例晚期非小细胞肺癌患者肺部肿瘤进一步缩小,胸腔积液、心包积液消失.病例1放射性核素骨显像示转移病灶放射性浓聚程度明显降低.病例2 MRI显示颅内多发转移病灶稳定.患者生活质量显著提高,KPS评分提高30,症状改善率达100%.不良反应为皮疹和腹泻(Ⅰ级),不需处理.结论 吉非替尼用于既往化疗显效的晚期非小细胞肺癌患者的维持治疗有较好的疗效和安全性.同时可改善患者的相关症状,提高生活质量.
目的 觀察吉非替尼對既往化學治療有效的晚期(Ⅳ期)非小細胞肺癌維持治療的療效和安全性.方法 在15例經病理學確診的非小細胞肺癌經4～6箇週期含鉑類方案化療後取得臨床完全緩解和部分緩解患者中,隨機選取2例Ⅳ期肺腺癌患者予以吉非替尼維持治療,250 mg/次,1次/d,口服.結果 2例晚期非小細胞肺癌患者肺部腫瘤進一步縮小,胸腔積液、心包積液消失.病例1放射性覈素骨顯像示轉移病竈放射性濃聚程度明顯降低.病例2 MRI顯示顱內多髮轉移病竈穩定.患者生活質量顯著提高,KPS評分提高30,癥狀改善率達100%.不良反應為皮疹和腹瀉(Ⅰ級),不需處理.結論 吉非替尼用于既往化療顯效的晚期非小細胞肺癌患者的維持治療有較好的療效和安全性.同時可改善患者的相關癥狀,提高生活質量.
목적 관찰길비체니대기왕화학치료유효적만기(Ⅳ기)비소세포폐암유지치료적료효화안전성.방법 재15례경병이학학진적비소세포폐암경4～6개주기함박류방안화료후취득림상완전완해화부분완해환자중,수궤선취2례Ⅳ기폐선암환자여이길비체니유지치료,250 mg/차,1차/d,구복.결과 2례만기비소세포폐암환자폐부종류진일보축소,흉강적액、심포적액소실.병례1방사성핵소골현상시전이병조방사성농취정도명현강저.병례2 MRI현시로내다발전이병조은정.환자생활질량현저제고,KPS평분제고30,증상개선솔체100%.불량반응위피진화복사(Ⅰ급),불수처리.결론 길비체니용우기왕화료현효적만기비소세포폐암환자적유지치료유교호적료효화안전성.동시가개선환자적상관증상,제고생활질량.
Objective To observe the efficacy and safety of gefitinib on maintenance therapy in patients with advanced (grade Ⅳ ) non-small cell lung cancer after effective chemotherapy. Methods Among 15 patients with non-small cell lung cancer confirmed pathologically who obtained complete response or partial response after 4-6 cycles of chemotherapy, two patients with advanced (grade Ⅵ) adenocarcinoma of lung were randomly selected to be administered gefitinib for maintenance therary, 250 mg,orally once a day. Results In two patients with advanced non-small cell lung cancer, lung tumor reduced further, pleural effusion and pericardial effusion disappeared. Radionuclide bone imaging of the first patient showed that radioactivity level of metastatic lesion reduced. Magnetic resonance imaging of the second patient showed that multiple intracranial metastatic lesions were stable. The quality of life improved significantly,KPS score increased by 30,and the improvement rate of symptom was 100%. The adverse reactions were rash and diarrhea (grade Ⅰ ) ,without treatment. Conclusions Gefitinib is effective and safe on maintenance therary of patients with advanced non-small cell lung cancer after effective chemotherapy. And it can improve the disease-related symptoms and the quality of life of patients.
